With Cash balance at end of quarter $14.4M (vs $14.3M as at 31 December, 2016)
AND Quarterly sales of $4.9M taking revenue for first 9 months to $17.2M, up 70% on the prior corresponding period (PCP) and on track to meet annual forecast
I would not be worried about the HSV-2, if it is good then it will be a huge + for SP if not then i do not think it will affect a lot on SP as you can see that the MC is too low and matket have never cared or included these vax programs into MC
Ann: HSV-2 Phase IIa Results Investor Webinar, page-13
-
- There are more pages in this discussion • 284 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
0.000(0.00%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $14.05 | $14.05 | $14.00 | $10.45K | 747 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 551 | $13.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.99 | 400 | 1 |
View Market Depth
| Last trade - 10.18am 08/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |